The REDUCE-IT trial, which evaluated the efficacy and safety of icosapent ethyl (IPE) in reducing cardiovascular events, found significant reductions in ischemic events with IPE compared to placebo, including a 37% reduction in the first primary composite outcome and a 36% reduction in total primary composite outcomes. These benefits were more pronounced in patients with recent acute coronary syndrome (ACS) (<12 months before randomization) compared to those with ACS ≥12 months before randomization. IPE also reduced the incidence of urgent or emergent revascularization by 44% and lowered the composite of cardiovascular death and non-fatal myocardial infarction by 36%. However, IPE increased the risk of atrial fibrillation or flutter, though not significantly. The study concluded that IPE can be safely initiated in high-risk, statin-treated patients with recent ACS to reduce the risk of ischemic events without increasing bleeding risk.The REDUCE-IT trial, which evaluated the efficacy and safety of icosapent ethyl (IPE) in reducing cardiovascular events, found significant reductions in ischemic events with IPE compared to placebo, including a 37% reduction in the first primary composite outcome and a 36% reduction in total primary composite outcomes. These benefits were more pronounced in patients with recent acute coronary syndrome (ACS) (<12 months before randomization) compared to those with ACS ≥12 months before randomization. IPE also reduced the incidence of urgent or emergent revascularization by 44% and lowered the composite of cardiovascular death and non-fatal myocardial infarction by 36%. However, IPE increased the risk of atrial fibrillation or flutter, though not significantly. The study concluded that IPE can be safely initiated in high-risk, statin-treated patients with recent ACS to reduce the risk of ischemic events without increasing bleeding risk.